Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Lee’s Pharma Gains Negotiation Option for China Rights to Anticoagulant

publication date: Jan 29, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Lee's Pharmaceutical of Hong Kong assumed responsibility for expanding into China a Phase III trial of a cardiovascular drug. In exchange, Lee’s will have an option to negotiate China rights for the drug. The drug, an anticoagulant called betrixaban, was developed by Portola Pharmaceuticals of San Francisco. Lee's will make upfront and continuing payments to Portola, which will support the China arm of the Phase III trial. Once the trial is concluded, Lee's will have an exclusive period – the duration was not specified – to negotiate China rights for betrixaban. More details....

Stock Symbol: (HK: 0950)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors